Unlike NK cells, CD16+ monocytes isolated from the same patients could lyse antibody-coated target cells as efficiently as CD16+ monocytes from healthy individuals for both SKBR3 cells and primary B-CLL cells (Fig. 7A,B; left panels respectively). This evidence concerns the gene FCGR3A and B-cell chronic lymphocytic leukemia.